FibroGen lands $350 million anemia drug deal with AstraZeneca
July 31, 2013 at 16:49 PM EDT
British drug giant AstraZeneca will pay $350 million to FibroGen Inc. for commercial rights to a drug to treat anemia associated with chronic kidney disease...